Arcutis Biotherapeutics (ARQT) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Arcutis Biotherapeutics (NASDAQ: ARQT):

• 12/8/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Arcutis Biotherapeutics was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/1/2025 – Arcutis Biotherapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Arcutis Biotherapeutics had its price target raised by analysts at Mizuho from $32.00 to $37.00. They now have an “outperform” rating on the stock.
• 11/1/2025 – Arcutis Biotherapeutics was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/30/2025 – Arcutis Biotherapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $29.00. They now have a “neutral” rating on the stock.
• 10/29/2025 – Arcutis Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
• 10/29/2025 – Arcutis Biotherapeutics was given a new $32.00 price target on by analysts at Mizuho.
• 10/29/2025 – Arcutis Biotherapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/28/2025 – Arcutis Biotherapeutics had its price target raised by analysts at Needham & Company LLC from $22.00 to $30.00. They now have a “buy” rating on the stock.
• 10/14/2025 – Arcutis Biotherapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Sue-Jean Lin sold 25,272 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $30.78, for a total transaction of $777,872.16. Following the transaction, the director directly owned 26,735 shares in the company, valued at approximately $822,903.30. This represents a 48.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Patrick Burnett sold 17,250 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.18, for a total value of $417,105.00. Following the sale, the insider directly owned 98,325 shares in the company, valued at $2,377,498.50. This trade represents a 14.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 327,729 shares of company stock valued at $8,305,217 in the last three months. Insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.